Royal Bank of Canada cut its holdings in Cardiovascular Systems, Inc. (NASDAQ:CSII) by 35.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,295 shares of the medical device company’s stock after selling 6,609 shares during the period. Royal Bank of Canada’s holdings in Cardiovascular Systems were worth $396,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CSII. BNP Paribas Arbitrage SA increased its holdings in shares of Cardiovascular Systems by 160.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock worth $166,000 after buying an additional 3,165 shares during the last quarter. UBS Asset Management Americas Inc. increased its holdings in shares of Cardiovascular Systems by 809.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 8,393 shares of the medical device company’s stock worth $237,000 after buying an additional 7,470 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Cardiovascular Systems by 2.9% in the 2nd quarter. Legal & General Group Plc now owns 7,763 shares of the medical device company’s stock worth $249,000 after buying an additional 216 shares during the last quarter. Advisor Group Inc. increased its holdings in shares of Cardiovascular Systems by 0.4% in the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock worth $263,000 after buying an additional 35 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Cardiovascular Systems by 34.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock valued at $265,000 after purchasing an additional 2,115 shares during the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/16/royal-bank-of-canada-trims-stake-in-cardiovascular-systems-inc-csii.html.

In other Cardiovascular Systems news, Director Edward M. Brown sold 13,031 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $29.09, for a total value of $379,071.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Brown sold 20,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $29.16, for a total transaction of $583,200.00. The disclosure for this sale can be found here. 3.30% of the stock is owned by insiders.

Several equities analysts recently commented on CSII shares. Citigroup Inc. started coverage on shares of Cardiovascular Systems in a report on Thursday, September 21st. They set a “market perform” rating on the stock. Needham & Company LLC reiterated a “buy” rating and set a $37.00 price target on shares of Cardiovascular Systems in a report on Thursday, October 12th. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Raymond James Financial, Inc. started coverage on shares of Cardiovascular Systems in a report on Friday, September 22nd. They set a “market perform” rating on the stock. Finally, BidaskClub downgraded shares of Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $38.00.

Cardiovascular Systems, Inc. (CSII) opened at $23.43 on Thursday. The company has a market cap of $775.19, a PE ratio of 1,174.00 and a beta of 2.53. Cardiovascular Systems, Inc. has a fifty-two week low of $23.00 and a fifty-two week high of $33.11. The company has a current ratio of 4.30, a quick ratio of 3.83 and a debt-to-equity ratio of 0.18.

Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, October 25th. The medical device company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $49.70 million for the quarter, compared to the consensus estimate of $51.00 million. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The firm’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) EPS. equities analysts predict that Cardiovascular Systems, Inc. will post -0.05 earnings per share for the current fiscal year.

Cardiovascular Systems Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSII).

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.